Researchers around the world have pursued the holy grail of diagnostic testing for IC/BPS – a simple, non-invasive urine test. Researchers at Beaumont Hospital, the nations leading IC research center, have developed a urine test which corrects classified all Hunner’s lesion patients. Simply astonishing!
In the IP4IC study, researchers measured urinary cytokine levels in 146 IC patients and 262 asymptomatic controls. A separate smaller dataset, P3, was collected in the clinic with physician documented diagnosis.
This method correctly classified 146 of 146 (100%) IC participants, both with and without Hunner’s lesions, and 262 of 262 (100%) control participants in the training set. For the validation set, 100% (N=26/26) IC patients and 96.3% (N=26/27) controls were correctly identified. A combination of both non-invasive urinary cytokines as well as pain and symptom scores was required for a classifier with strong validity. This may be the holy grail of new diagnostic testing for IC. It is high confidence urine test that could drive a personalized medical diagnosis of patients with suspicion of IC based on inflammation and pain and symptoms.
Source: Lamb L, et al. MP39-11 TOWARD PERSONALIZED MEDICINE FOR AN INTERSTITIAL CYSTITIS INDIVIDUALIZED DIAGNOSIS USING A NEW BLADDER INFLAMMATION SCORE – AUA 2018 Annual Meeting Poster Session